https://orcid.org/0000-0002-3424-5175
Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Stefano Dastoli, Maria Passante, Francesco Loconsole, Edoardo Mortato, Anna Balato, Vincenzo Piccolo, Claudio Guarneri, Laura Macca, Eugenio Provenzano, Giancarlo Valenti, Domenico D’Amico, Giuseppe Micali, Maria Letizia Musumeci, Giovanni Palazzo, Caterina Foti, Paolo Romita, Gabriella Fabbrocini, Matteo Megna, Ilaria Sammarra, Luigi Bennardo & Cataldo Patruno. (2023) Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. Journal of Dermatological Treatment 34:1.
Read now
Read now
Francesco Messina & Stefano Piaserico. (2022) The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition. Journal of Dermatological Treatment 33:5, pages 2443-2454.
Read now
Read now
Marco Galluzzo, Marina Talamonti, Laura Atzori, Federico Bardazzi, Anna Campanati, Antonella Di Cesare, Federico Diotallevi, Maria Laura Flori, Cristina Mugheddu, Annamaria Offidani, Stefano Piaserico, Filomena Russo, Lidia Sacchelli, Luca Bianchi & Francesca Prignano. (2022) Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opinion on Biological Therapy 22:4, pages 547-554.
Read now
Read now
Fatma Elif Yıldırım & Fatma Aslı Hapa. (2022) Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey. Journal of Dermatological Treatment 33:3, pages 1531-1537.
Read now
Read now
Bénédicte Caron, Jean-Yves Jouzeau, Pierre Miossec, Nadine Petitpain, Pierre Gillet, Patrick Netter & Laurent Peyrin-Biroulet. (2022) Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opinion on Drug Safety 21:2, pages 223-239.
Read now
Read now
Marco Galluzzo, Valeria Manfreda, Alessandra Petruzzellis, Luca Bianchi & Marina Talamonti. (2021) The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis. Expert Review of Precision Medicine and Drug Development 6:2, pages 131-137.
Read now
Read now
Martina Morelli, Marco Galluzzo, Stefania Madonna, Claudia Scarponi, Giovanni Luca Scaglione, Tiziana Galluccio, Marco Andreani, Sabatino Pallotta, Giampiero Girolomoni, Luca Bianchi, Marina Talamonti & Cristina Albanesi. (2021) HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert Opinion on Biological Therapy 21:2, pages 259-270.
Read now
Read now
Marco Galluzzo, Lorenzo Tofani, Luca Bianchi & Marina Talamonti. (2020) Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. Expert Opinion on Biological Therapy 20:8, pages 829-830.
Read now
Read now
Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu & Yuebin Zeng. Risk of candidiasis associated with interleukin-17 inhibitors: implications and management. Mycology 0:0, pages 1-15.
Read now
Read now
Articles from other publishers (18)
Jian Zhou, Yuan Yuan, Yanhua Liu, Mengyang Chu, Huan Liu, Qian Liu, Rui Wang, Shuai Shao, Gang Wang & Chen Yu. (2023) Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice. Experimental Dermatology.
Crossref
Crossref
Emilio Berna-Rico, Javier Perez-Bootello, Carlota Abbad-Jaime de Aragon & Alvaro Gonzalez-Cantero. (2023) Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine. International Journal of Molecular Sciences 24:12, pages 9850.
Crossref
Crossref
Estela García-Martín, RM Romero-Jiménez, Ofelia Baniandrés-Rodríguez, Vicente Escudero-Vilaplana, Juana Benedí-González, Paloma Morales de los Ríos Luna, Ana Herranz-Alonso & María Sanjurjo-Sáez. (2023) Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors. European Journal of Hospital Pharmacy, pages ejhpharm-2022-003594.
Crossref
Crossref
Hao Trong Nguyen, Nhi Thi Uyen Pham, Tu Nguyen Anh Tran, Nguyen Nhat Pham, Yen Thi Bui & Thao Thi Phuong Vu. (2022) Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study. Dermatology and Therapy 13:2, pages 465-476.
Crossref
Crossref
Kim A. Papp, Melinda Gooderham, Ignacio Dei-Cas, Adriana LopezTello, Juan C. Garcia-Rodriguez, Carmen Yris Taveras, Azucena Hernández Rousselin, Alberto Lavieri, Mónica Maiolino, Delfina Guadalupe Villanueva Quintero, Lenka Rihakova, Mariano Salibe & Wilfran Pertuz. (2022) Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatology and Therapy 13:1, pages 269-283.
Crossref
Crossref
Pablo Chicharro, Mar Llamas‐Velasco, Susana Armesto, Enrique Herrera Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera‐Diaz, Pablo De‐la‐Cueva, Antonio Martorell‐Calatayud, Ferran Ballescà, Isabel Belinchon, Gregorio Carretero, Lourdes Rodriguez, Alberto Romero‐Maté, Josep Pujol‐Montcusí, Laura Salgado, Antonio Sahuquillo‐Torralba, Pablo Coto‐Segura, Ofelia Baniandrés Rodríguez, Rosa Feltes, José Riera‐Monroig & Esteban Dauden. (2022) Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy 35:12.
Crossref
Crossref
Xi‐Bei Chen, Yu‐Xin Zheng, Li‐Ran Ye, Xue‐Yan Chen & Xiao‐Yong Man. (2022) Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks. Dermatologic Therapy 35:12.
Crossref
Crossref
Peter Foley, Lynda Spelman, Dedee F. Murrell, Eric Mate, Rebecca Tronnberg & Patricia M. Lowe. (2022)
Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the
HOPE
study
. Australasian Journal of Dermatology 63:3, pages 312-320.
Crossref
Crossref
Jensen Yeung, Paul E. Bunce, Charles W. Lynde, Irina Turchin & Ronald B. Vender. (2022) Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies. Journal of Cutaneous Medicine and Surgery 26:1_suppl, pages 3S-23S.
Crossref
Crossref
Giovanni Damiani, Giulia Odorici, Alessia Pacifico, Aldo Morrone, Rosalynn R. Z. Conic, Tima Davidson, Abdulla Watad, Paolo D. M. Pigatto, Delia Colombo, Piergiorgio Malagoli & Marco Fiore. (2022) Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching. Pharmaceuticals 15:1, pages 95.
Crossref
Crossref
Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi, Giuseppe Argenziano, Silvana Ruffolo, Paolo Dapavo, Carlo Carrera, Maria Concetta Fargnoli, Aurora Parodi, Marco Romanelli, Piergiorgio Malagoli, Marina Talamonti, Matteo Megna, Massimo Raspanti, Matteo Paolinelli, Katharina Hansel, Alessandra Narcisi, Andrea Conti, Clara De Simone, Marco Adriano Chessa, Alina De Rosa, Eugenio Provenzano, Michela Ortoncelli, Chiara Moltrasio, Rosaria Fidanza, Martina Burlando, Annalisa Tonini, Francesca Maria Gaiani, Lucia Simoni, Alessandra Ori, Martina Fiocchi & Emanuela Zagni. (2021)
Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the
CANOVA
(
EffeCtiveness
of biologic
treAtmeNts
for plaque
psOriasis
in Italy: An
obserVAtional
longitudinal study of real‐life clinical practice) study
. Dermatologic Therapy 35:1.
Crossref
Crossref
Leyla S. Namazova-Baranova, Andrey L. Bakulev, Nikolay N. Murachkin, Lyudmila N. Nam & Roman A. Ivanov. (2021) Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs. Current Pediatrics 20:5, pages 446-450.
Crossref
Crossref
Paulo Ferreira & Pedro Mendes‐Bastos. (2021) Secukinumab: A complete approach to psoriatic patients—Real‐world evidence study. Dermatologic Therapy 34:2.
Crossref
Crossref
Scott H Berg, Esther A Balogh, Rima I Ghamrawi & Steven R Feldman. (2021) A review of secukinumab in psoriasis treatment. Immunotherapy 13:3, pages 201-216.
Crossref
Crossref
Nikolai Loft, Anne-Sofie Halling, Alexander Egeberg & Lone Skov. (2021) Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology 84:1, pages 130-138.
Crossref
Crossref
Dan Shu, Zhuying Zhang, Eray Yihui Zhou, Xuzhu Ma & Yi Zhao. (2020)
Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving
IL
‐17 inhibitors? A cohort study
. Dermatologic Therapy 33:6.
Crossref
Crossref
Ilke Coskun Benlidayi, Behice Kurtaran, Emre Tirasci & Rengin Guzel. (2020) Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. Rheumatology International 40:10, pages 1707-1716.
Crossref
Crossref
J.L.W. Lambert, S. Segaert, P.D. Ghislain, T. Hillary, A. Nikkels, F. Willaert, J. Lambert & R. Speeckaert. (2020) Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2). Journal of the European Academy of Dermatology and Venereology 34:9, pages 1914-1923.
Crossref
Crossref